Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Rheumatoid arthritis of \>/= 1 year duration~* Mild to moderate disease activity at screening (DAS 28 \</= 4.5 and \>2.6)~* On methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to Day 1~* Body weight \</= 150 kg~* Oral corticosteroids must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline~* Rheumatic autoimmune disease other than rheumatoid arthritis~* Functional class IV American College of Rheumatology (ACR) Classification~* Prior history of or current inflammatory joint disease other than rheumatoid arthritis~* Treatment with a biologic agent at any time prior to baseline~* Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline~* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* Previous treatment with tocilizumab~* Pregnant or lactating women~* Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids~* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections~* History of or currently active primary or secondary immunodeficiency~* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years~* Active tuberculosis requiring treatment within the previous 3 years~* Positive for HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A Methotrexate (Type: ACTIVE_COMPARATOR): None
- B Methotrexate Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).